Immunome Inc. (IMNM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Immunome reported revenue of $6.9M, down 23.2% from $9.0M the year before. Net income was -$212.4M (a -3060.0% net margin), or -$2.43 per diluted share. Operating margin was -3228.8%. Operating activities generated -$190.9M of cash, leaving -$200.6M of free cash flow. At fiscal year end, Immunome held $683.2M in total assets against $48.8M in total liabilities, including $653.5M of cash and equivalents.
Open the full interactive Immunome financials → Quarterly statements, key ratios, valuation history and price charts.
Immunome Key Stats
| Share Price | $17.58 |
|---|---|
| Market Cap | $1.99B |
| Revenue YoY Growth | -23.2% |
| 52-Week Range | $14.10 – $29.83 |
| Shares Outstanding | 113.3 million (basic, 2026 Q2) |
Immunome Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $14.0M | $9.0M | $6.9M |
| Operating Income | -$12.3M | -$25.2M | -$36.9M | -$109.5M | -$305.8M | -$224.1M |
| Pre-Tax Income | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| Diluted EPS | -$5.26 | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
Immunome Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$57.5M | -$69.9M | -$53.8M | -$73.1M |
| Diluted EPS | -$0.65 | -$0.80 | -$0.48 | -$0.65 |
Immunome Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.8M | $49.2M | $20.3M | $98.7M | $143.4M | $653.5M |
| Current Assets | $42.9M | $56.6M | $22.6M | $144.7M | $221.3M | $660.8M |
| Total Assets | $44.5M | $57.9M | $24.0M | $148.5M | $240.2M | $683.2M |
| Current Liabilities | $3.0M | $9.7M | $7.3M | $21.8M | $54.3M | $45.0M |
| Total Long-Term Debt | $500,000 | — | — | — | — | — |
| Total Liabilities | $3.2M | $9.7M | $7.4M | $28.7M | $59.1M | $48.8M |
| Shareholders' Equity | $41.3M | $48.2M | $16.7M | $119.9M | $181.2M | $634.3M |
Immunome Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.1M | -$18.2M | -$28.7M | -$7.6M | -$110.8M | -$190.9M |
| Cash From Investing | -$586,000 | -$79,000 | -$248,000 | -$30.5M | -$85.1M | $60.8M |
| Cash From Financing | $49.9M | $27.8M | $32,000 | $116.4M | $240.5M | $640.4M |
| Free Cash Flow | -$12.7M | -$18.3M | -$28.9M | -$8.4M | -$118.0M | -$200.6M |
Figures from Immunome's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immunome financials page for every line item.
Immunome Company Profile
| Ticker | IMNM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bothell, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer |
| SEC CIK | 0001472012 |
Frequently Asked Questions
What was Immunome's revenue in fiscal 2025?
Immunome (IMNM) reported revenue of $6.9M for fiscal 2025.
What is Immunome's annual revenue history?
Immunome's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $14.0M; 2024: $9.0M; 2025: $6.9M.
What was Immunome's net income in fiscal 2025?
Immunome reported net income of -$212.4M for fiscal 2025.
What was Immunome's earnings per share (EPS) in fiscal 2025?
Immunome's diluted EPS was -$2.43 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Immunome generate in fiscal 2025?
Immunome generated -$200.6M of free cash flow in fiscal 2025.
What was Immunome's revenue last quarter?
In its most recent reported quarter (2026 Q2), Immunome reported revenue of $0.
How many shares of Immunome are outstanding?
Immunome reported a weighted average of 113.3 million basic shares outstanding in 2026 Q2.
What is Immunome's market cap?
Based on its latest closing price, Immunome (IMNM) has a market capitalization of about $1.99B.
When does Immunome's fiscal year end?
Immunome's fiscal year end, as registered with the SEC, is December 31.
Where is Immunome headquartered?
Immunome lists its business address in Bothell, Washington in its SEC filings.